Research & Development
Biological Dynamics embarks on clinical utility studies for pancreatic cancer detection assay
Biological Dynamics said that it is collaborating with Qure Healthcare and Curta to also evaluate the effects of its pancreatic cancer detection assay on patient outcomes and healthcare economics.
November 23, 2022
University of Pittsburgh NGS test shows high sensitivity in pancreatic cyst study
By sequencing 22 pancreatic cyst-associated genes, the PancreaSeq test distinguished benign cysts from those that could become cancerous.
October 6, 2022
Immunovia nabs CMS preliminary payment determination
The CMS preliminary payment determination implied a test price of $897.
September 26, 2022
Immunovia nabs California approval for pancreatic cancer test
The California Department of Public Health has granted Immunovia a clinical and public health laboratory license for the test, Immunovia said Thursday.
August 10, 2022
Guardant highlights data on multicancer test at AACR 2022
Guardant Shield analyzes about 20,000 epigenomic markers with a single blood test. In the data presented at AACR 2022, researchers showed the efficacy of Guardant Shield in the detection of four types of early-stage cancers: colorectal, lung, pancreatic, and bladder.
April 12, 2022
AI spots patients at elevated risk for pancreatic cancer
A team of researchers from the U.S. and Denmark used electronic health record (EHR) data from the Danish National Patient Registry to train their algorithm and then tested it on electronic medical records from Mass General Brigham Health Care System in Boston. Their model proved to be highly accurate for predicting patients at high risk for pancreatic cancer on large datasets from both countries.
April 8, 2022
DNA forensic evidence frees Ohio man of rape, attempted rape
Low-value prostate cancer screening has Medicare spending ramifications, study finds
Empatica receives FDA clearance for digital biomarker platform, closes Series B financing
‘Good’ cholesterol worse for some adults: NIH study
PerkinElmer launches adeno-associated virus vector detection kits for research
Widespread HbA1c screening enables earlier type 2 diabetes diagnosis in U.K. study
Immunovia touts performance of PanCan-d test in clinical study
The test detected pancreatic ductal adenocarcinoma with 99% specificity and 89% sensitivity in stage I/II when excluding individuals with low levels of CA 19-9, an antigen released by pancreatic cancer cells.
February 17, 2022
PerkinElmer introduces 4 new ready-to-use KRAS assay kits
Designed to help researchers better understand KRAS protein structures and mutations, the kits all come with recombinant proteins, detection reagents, and assay buffers, according to the company.
July 28, 2021
PanCan, GeneCentric partner on precision medicine for pancreatic cancer
The partnership is designed to improve treatment response and survival rates of patients with pancreatic ductal adenocarcinoma (PDAC) tumors. It will utilize PanCan's patient molecular and outcomes data and GeneCentric's RNA-based portfolio, which includes the PurlSt profiler that identifies PDAC subtypes.
July 30, 2020
AI predicts which patients to test for pancreatic cancer
The researchers matched 1,378 patients in the U.K. who developed pancreatic cancer with four people of the same age and sex who developed another type of cancer. They then created a model to predict an individual's cancer risk using the patients' electronic health records data from general physician appointments. The data included the patients' symptoms, diseases, and medications up to two years before their cancer diagnosis.
July 5, 2020
Caris to highlight precision medicine at ASCO 2020
The research to be presented includes results from studies of multiple cancer types, such as colorectal, pancreatic, lung, and breast cancer, according to the firm.
May 11, 2020
Blood test bolsters imaging for staging pancreatic cancer
The researchers evaluated circulating cell-free DNA using quantitative polymerase chain reaction (qPCR) technology in patients with PDAC, which they noted is the most common type of pancreatic cancer and the third leading cause of cancer-related death in the U.S., with very low survival rates. Diagnosis and staging are currently done with ultrasound-guided biopsy, computed tomography, and magnetic resonance imaging.
April 15, 2020
Page 1 of 2